Brought to you by 
Jennerex grants Transgene exclusive rights to JX594
15 Nov 2021
Executive Summary
Jennerex Biotherapeutics Inc. (cancer) has granted immunotherapeutics company Transgene SA exclusive rights to develop and commercialize its Phase II solid tumor candidate JX594 in Europe, the Commonwealth of Independent States (CIS), and the Middle East.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Jennerex grants Transgene exclusive rights to JX594
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice